125 related articles for article (PubMed ID: 34617383)
1. Patterns of care and outcomes for gastric and gastro-oesophageal junction cancer in an Australian population.
Abbas MN; Bright T; Price T; Karapetis C; Thompson S; Connell C; Watson D; Barnes M; Bull J; Singhal N; Roy A
ANZ J Surg; 2021 Dec; 91(12):2675-2682. PubMed ID: 34617383
[TBL] [Abstract][Full Text] [Related]
2. Laparoscopy, computerised tomography and fluorodeoxyglucose positron emission tomography in the management of gastric and gastro-oesophageal junction cancers.
Mirza A; Galloway S
Surg Endosc; 2016 Jul; 30(7):2690-6. PubMed ID: 26487234
[TBL] [Abstract][Full Text] [Related]
3. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
4. The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona.
Van Laethem JL; Carneiro F; Ducreux M; Messman H; Lordick F; Ilson DH; Allum WH; Haustermans K; Lepage C; Matysiak-Budnik T; Cats A; Schmiegel W; Cervantes A; Van Cutsem E; Rougier P; Seufferlein T
Dig Liver Dis; 2016 Nov; 48(11):1283-1289. PubMed ID: 27590840
[TBL] [Abstract][Full Text] [Related]
5. Geographical differences in cancer treatment and survival for patients with oesophageal and gastro-oesophageal junctional cancers.
Jestin Hannan C; Linder G; Kung CH; Johansson J; Lindblad M; Hedberg J
Br J Surg; 2020 Oct; 107(11):1500-1509. PubMed ID: 32484241
[TBL] [Abstract][Full Text] [Related]
6. Improving care for patients with oesophageal and gastric cancer: impact of a statewide multidisciplinary team.
Wilson EE; Thompson SK; Bull J; Jones B; Price T; Devitt PG; Watson DI; Bright T
ANZ J Surg; 2016 Apr; 86(4):270-3. PubMed ID: 25288355
[TBL] [Abstract][Full Text] [Related]
7. [Survival comparison of Siewert II adenocarcinoma of esophagogastric junction between transthoracic and transabdominal approaches:a joint data analysis of thoracic and gastrointestinal surgery].
Yang S; Yuan Y; Hu H; Li R; Liu K; Zhang W; Yang K; Yang Y; Bai D; Chen X; Zhou Z; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):132-142. PubMed ID: 30799535
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of the value of 7th editions of UICC-AJCC esophageal and gastric cancer TNM staging systems for prognostic prediction of adenocarcinoma of esophagogastric junction (Siewert type II)].
Shi GD; Luo ZL; Fu MY; Tian D; Zhang L; Zhang KP
Zhonghua Zhong Liu Za Zhi; 2014 Dec; 36(12):916-21. PubMed ID: 25623766
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of survival and prognosis of Siewert Ⅱ/Ⅲ esophagogastric junction adenocarcinoma patients with non-operative acute upper gastrointestinal hemorrhage].
Tian L; Yu L
Zhonghua Yi Xue Za Zhi; 2020 Jun; 100(24):1881-1885. PubMed ID: 32575932
[No Abstract] [Full Text] [Related]
10. Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer.
Wagner AD; Lordick F; Grabsch HI; Terashima M; Terada M; Yoshikawa T; Boku N; Kataoka K; Smyth EC; Mauer M; Haustermans K; Moehler MH
Eur J Cancer; 2020 Jan; 124():67-76. PubMed ID: 31759294
[TBL] [Abstract][Full Text] [Related]
11. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
Rivera F; Izquierdo-Manuel M; García-Alfonso P; Martínez de Castro E; Gallego J; Limón ML; Alsina M; López L; Galán M; Falcó E; Manzano JL; González E; Muñoz-Unceta N; López C; Aranda E; Fernández E; Jorge M; Jiménez-Fonseca P
Eur J Cancer; 2021 Mar; 145():158-167. PubMed ID: 33485079
[TBL] [Abstract][Full Text] [Related]
12. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
13. Adenocarcinomas at different positions at the gastro-oesophageal junction show distinct association with gastritis and gastric preneoplastic conditions.
Bornschein J; Dingwerth A; Selgrad M; Venerito M; Stuebs P; Frauenschlaeger K; Achilleos A; Roessner A; Malfertheiner P
Eur J Gastroenterol Hepatol; 2015 May; 27(5):492-500. PubMed ID: 25822856
[TBL] [Abstract][Full Text] [Related]
14. Clinical profile of carcinoma stomach at a tertiary care hospital in south India.
Sambasivaiah K; Ibrarullah M; Reddy MK; Reddy PV; Wagholikar G; Jaiman S; Reddy DG; Sarma KV; Hegde GN
Trop Gastroenterol; 2004; 25(1):21-6. PubMed ID: 15303466
[TBL] [Abstract][Full Text] [Related]
15. Current state of surgical treatment of cancer of the stomach and gastro-esophageal junction in the Czech Republic.
Duda M; Dušek L; Jínek T; Adamčík L; Škrovina M
Rozhl Chir; 2018; 97(7):309-319. PubMed ID: 30442012
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Boku N; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Chen LT
Lancet; 2017 Dec; 390(10111):2461-2471. PubMed ID: 28993052
[TBL] [Abstract][Full Text] [Related]
17. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis.
Kumagai K; Rouvelas I; Tsai JA; Mariosa D; Lind PA; Lindblad M; Ye W; Lundell L; Schuhmacher C; Mauer M; Burmeister BH; Thomas JM; Stahl M; Nilsson M
Eur J Surg Oncol; 2015 Mar; 41(3):282-94. PubMed ID: 25491892
[TBL] [Abstract][Full Text] [Related]
18. The role of staging investigations for oesophago-gastric carcinoma.
Clements DM; Bowrey DJ; Havard TJ
Eur J Surg Oncol; 2004 Apr; 30(3):309-12. PubMed ID: 15028314
[TBL] [Abstract][Full Text] [Related]
19. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
[TBL] [Abstract][Full Text] [Related]
20. Impact of multidisciplinary tumor board discussion on palliation of patients with esophageal or gastro-esophageal junction cancer: a population-based study.
Vermeulen BD; Bruggeman L; Bac DJ; Schrauwen RWM; Epping LSM; Scheffer RCH; Tan ACITL; Groenen MJM; Verhoeven RHA; Siersema PD
Acta Oncol; 2020 Apr; 59(4):410-416. PubMed ID: 32067535
[No Abstract] [Full Text] [Related]
[Next] [New Search]
